New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:03 EDTPFE, MYLMylan settles patent litigation related to Celebrex capsules with Pfizer
Mylan (MYL) announced that it has entered into a settlement and license agreement with Pfizer (PFE) relating to Mylan's Abbreviated New Drug Application filed with the FDA for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg. This product is the generic version of Celebrex, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Under the terms of the agreement, Mylan will begin selling product at the earliest market formation, however in any case not later than December. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. Additionally, Mylan has appealed the decision by the United States District Court for the Northern District of West Virginia denying Mylan's request for an injunction in its suit against the FDA. Mylan continues to believe that FDA seriously erred in its decision awarding one party eligibility for 180 days of exclusivity on Celecoxib, and will continue with this suit independent of the aforementioned settlement.
News For MYL;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 2, 2015
16:12 EDTMYLMylan reports Q4 adjusted EPS $1.05, consensus $1.05
Reports Q4 revenue $2.08B, consensus $2.07B.
15:23 EDTMYLNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Mylan (MYL), consensus $1.05... Nabors Industries (NBR), consensus 39c... PRA Group (PRAA), consensus $1.11... Caesars Entertainment (CZR), consensus ($1.65)... Cumulus Media (CMLS), consensus 9c... Arena Pharmaceuticals (ARNA), consensus (12c)... Palo Alto Networks (PANW), consensus 17c... Guidewire Software (GWRE), consensus 11c... McDermott International (MDR), consensus (6c)... Salix Pharmaceuticals (SLXP), consensus (25c)... Matador Resources (MTDR), consensus 19c... Sanchez Energy (SN), consensus (11c).
09:02 EDTPFEAstraZeneca mulls linking bonuses to Pfizer defense pledges, Sunday Times says
Subscribe for More Information
08:47 EDTMYLMylan volatility elevated into Q4 and outlook
Subscribe for More Information
February 27, 2015
15:09 EDTMYLMylan files to sell 110M ordinary shares for selling shareholders
12:35 EDTMYLMylan completes acquisition of assets from Abbott
Mylan N.V. and Mylan (MYL) announced the successful completion of the acquisition of Abbott Laboratories' (ABT) non-U.S. developed markets specialty and branded generics business. Under the previously announced terms of the transaction agreement, Abbott received 110M shares of Mylan N.V., resulting in former Mylan shareholders now owning approximately 78% of Mylan N.V. and Abbott now owning approximately 22% of Mylan N.V. Mylan Inc. and Abbott's non-U.S. developed markets specialty and branded generics business have been reorganized under Mylan N.V., a new public company organized in the Netherlands. Mylan N.V. will be led by the former Mylan Inc. executive team. The company will trade on Nasdaq under the ticker symbol MYL.
February 26, 2015
12:31 EDTPFEPfizer says CDC recommends serogroup B meningococcal vaccine for those at risk
Subscribe for More Information
February 24, 2015
08:07 EDTPFEPfizer announces Trumenba studies met primary objectives
Subscribe for More Information
February 23, 2015
07:16 EDTMYLMylan signs exclusive agreement with Gilead to distribute Solvaldi, Harvoni
Subscribe for More Information
February 20, 2015
10:33 EDTPFEBattleground update: AbbVie named top global pick at Jefferies
Subscribe for More Information
10:31 EDTPFEPfizer announces FDA acceptance of NDA for Rapamune
Pfizer announced that the FDA has accepted for priority review a supplemental New Drug Application for RAPAMUNE for the treatment of lymphangioleiomyomatosis, a rare, progressive lung disease in women of childbearing age that is often fatal. With the Priority Review designation for the sNDA, Pfizer anticipates a decision in June of 2015 based on the anticipated Prescription Drug User Fee Act action date. The sNDA is based on results from the Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus Trial. The MILES Trial included 89 LAM patients with moderate lung impairment who were randomized to receive RAPAMUNE or placebo for 12 months, followed by a 12 month observation period. In the trial, those treated with RAPAMUNE for one year experienced stabilization of lung function as measured by forced expiratory volume in one second.
07:23 EDTPFEAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTMYLAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 19, 2015
18:25 EDTPFEPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
14:49 EDTPFEWalgreens selected by Pfizer as one of pharmacies to dispense Ibrance
Subscribe for More Information
07:12 EDTPFEWharton Health Care Club to hold a conference
Subscribe for More Information
February 18, 2015
08:41 EDTMYLThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
February 17, 2015
18:06 EDTMYLPaulson & Co gives quarterly update on stakes
Subscribe for More Information
15:36 EDTPFETianyin JCM plans for FDA certification process
Tianyin Pharmaceutical (TPI) updated on the business and development at its Jiangchuan Macrolide Facility, or JCM, active pharmaceutical ingredients operation. In addition to JCM's certification at India, along with other international clients located at Bangladesh, Philippines and Iran on import status, TPI plans for FDA certification process at its JCM facility in order to service international clients such as Pfizer's (PFE) and their subsidiaries in China, the company said. "This is expected to translate to further demand for JCM's macrolide API business in both the domestic and international markets," Tianyin stated.
10:01 EDTPFECVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use